Investor Information Available At:
CanniMed News Banner

 News

CanniMed Therapeutics Inc. Statement Regarding CSA/TSX Staff Notice on Issuers with U.S. Marijuana – Related Activities


CANNIMED THERAPEUTICS INC.

Saskatoon, SaskatchewanOctober 17, 2017 – CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) does not carry on any marijuana related activities in the United States and has not invested into any cannabis-based business in the United States. The Company abides by all Federal US policies and laws in this regard.

The announcements by the Canadian Securities Administrators (CSA) and the Toronto Stock Exchange (TSX) on Monday, October 16 are not expected to impact any of the Company’s business operations. Moreover, the Company does not believe that it is required to provide additional disclosure as contemplated in the notice for issuers with U.S. marijuana related activities.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 16 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

The Company, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

For more information, please visit our websites: www.cannimed.ca (patients) and www.cannimedtherapeutics.com (investors).

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed Therapeutics Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks described in CanniMed Therapeutics Inc.’s documents filed with applicable Canadian securities regulatory authorities which may be viewed at www.sedar.com. The forward-looking statements included in this news release are made as of the date of this news release. CanniMed Therapeutics Inc. does not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities legislation.

For more information or to schedule an interview, please contact:

Dara Willis
CanniMed Therapeutics Inc.
(416) 836-9272
media@cannimed.com